The European Medicines Agency has issued guidance outlining the regulatory requirements companies will need to meet if they plan to modify their coronavirus vaccines to address new SARS-CoV-2 variants.
The guidance was published on the same day that EU heads of state and government pledged to support efforts to increase vaccine production and R&D and to adjust vaccines...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?